Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24. DOI: 10.4014/jmb.2003.03011
DOI: https://doi.org/10.4014/jmb.2003.03011
Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clínica Española. 2021;221(1):55–61. DOI: 10.1016/j.rce.2020.03.001
DOI: https://doi.org/10.1016/j.rce.2020.03.001
Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019 -COVID-19. Clin Microbiol Rev [Internet]. 2020;33(4):1–48. Available from: DOI: https://doi.org/10.1128/CMR.00028-20
DOI: https://doi.org/10.1128/CMR.00028-20
Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667–73. DOI: 10.1016/j.jiph.2020.03.019
DOI: https://doi.org/10.1016/j.jiph.2020.03.019
Centros para el Control y la prevención de Enfermedades. Sindrome respiratorio agudo severo. C.D.F. 2004. https://www.cdc.gov/sars/index-sp.html
Yang Y, Xiao Z, Ye K, He X, Sun B, Qin Z, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020;17(1):1–17. DOI: https://doi.org/10.1186/s12985-020-01369-z
DOI: https://doi.org/10.1186/s12985-020-01369-z
Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–44. DOI: 10.1016/S1473-3099(20)30484-9.
DOI: https://doi.org/10.1016/S1473-3099(20)30484-9
Díaz-Castrillón FJ, Toro-Montoya AI. SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia. Med y Lab. 2020;24(3):183–205. DOI: https://doi.org/10.36384/01232576.268
DOI: https://doi.org/10.36384/01232576.268
José FG, González JGÁ, Molina JMC, Arnau LB, Iribarren IM, Jabaloyas JMM, et al. SARS-CoV-2 infection: implications for sexual and reproductive health. A position statement of the Asociación Española de Andrología, Medicina Sexual y Reproductiva (ASESA). Rev Int Androl. 2020;18(3):117–23. DOI: 10.1016/j.androl.2020.06.001.
DOI: https://doi.org/10.1016/j.androl.2020.06.001
Yuki K et al. Review Article COVID-19 pathophysiology: A review. Clin Immunol [Internet]. 2020;215(January):1–8. DOI https://doi.org/10.1016/j.clim.2020.108427
DOI: https://doi.org/10.1016/j.clim.2020.108427
Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36. DOI: 10.1080/22221751.2020.1719902
DOI: https://doi.org/10.1080/22221751.2020.1719902
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2021. Available from: https://covid19.who.int
Social M de S y P. Colombia confirma su primer caso de COVID-19 [Internet]. Boletin de prensa No. 050 de 2020. 2020. Available from: https://www.minsalud.gov.co/Paginas/Colombia-confirma-su-primer-caso-de-COVID-19.aspx
Toledo JD, Bernal C, Ramírez B, Rodríguez S, Vallejo M, Rivera D, et al. SEGUIMIENTO COVID-19 COLOMBIA 30 -SEPTIEMBRE-2020 Dia 206 del Brote en Colombia. Bogotá D.C; 2020.Fuente: Comunicación personal.
Organización Panamericana de la Salud. Indicadores incidencia y Gravedad Actualización situación COVID-19 Colombia. Inst Nac Salud, Obs Nac Salud. 2020;(151):1–9. https://www.paho.org/es/reportes-situacion-covid-19-colombia
Organización Panamericana de la Salud. Reporte de Situacion COVID-19 Colombia No. 206 - 02 de febrero 2021 Indicadores de incidencia. Colombia; 2020. https://www.paho.org/es/reportes-situacion-covid-19-colombia
Care E point of. Coronavirus: novel coronavirus (COVID-19) infection. Elsevier. 2020. p. 1–46. https://www.elsevier.com/__data/assets/pdf_file/0011/990722/Coronavirus-novel-coronavirus-COVID-19-infection-CO-200520.pdf
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–9. DOI: 10.1164/rccm.202003-0543OC
DOI: https://doi.org/10.1164/rccm.202003-0543OC
Thapa K, Mph B, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2020;49(January):238–46. DOI: 10.1016/j.ajic.2020.06.213
DOI: https://doi.org/10.1016/j.ajic.2020.06.213
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis, and treatment of COVID-19. J Antimicrob agents. 2020;55(January):1–13. DOI: 10.1016/j.ijantimicag.2020.105955
DOI: https://doi.org/10.1016/j.ijantimicag.2020.105955
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV) infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance. 2020;25(5):1–6. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062
DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062
Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100–15. DOI: 10.1016/j.it.2020.10.004
DOI: https://doi.org/10.1016/j.it.2020.10.004
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(January):607–13. DOI 10.1016/j.jinf.2020.03.037
DOI: https://doi.org/10.1016/j.jinf.2020.03.037
Alves A, Quispe A, Ávila A, Valdivia A, Chino J, Vera O. Breve historia y fisiopatologia del COVID-19. Guia Diagnostico y Trat COVID-19 en Unidades Ter Intensiva para Boliv. 2020;61(1):77–86. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-807138
Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertens y riesgo Vasc. 2020;37(4):176–80. DOI: 10.1016/j.hipert.2020.06.003
DOI: https://doi.org/10.1016/j.hipert.2020.06.003
Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43(10):1028–46. DOI: 10.1038/s41440-020-0515-0
DOI: https://doi.org/10.1038/s41440-020-0515-0
Kanwal A, Agarwala A, Warsinger Martin L, Handberg EM, Yang E. COVID-19 and Hypertension: What We Know and Don’t Know [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and-hypertension
Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Polish Arch Intern Med. 2020;130(4):304–9. DOI: 10.20452/pamw.15272
DOI: https://doi.org/10.20452/pamw.15272
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. DOI: 10.1016/j.jemermed.2020.04.004
DOI: https://doi.org/10.1056/NEJMoa2002032
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. DOI: 10.1111/joim.13091
DOI: https://doi.org/10.1111/joim.13091
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34(March):101623. DOI: 10.1016/j.tmaid.2020.101623
DOI: https://doi.org/10.1016/j.tmaid.2020.101623
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5. DOI: 10.1002/jmv.25728
DOI: https://doi.org/10.1002/jmv.25728
Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol - Head Neck Surg (United States). 2020;163(1):3–11. DOI: 10.1177/0194599820926473
DOI: https://doi.org/10.1177/0194599820926473
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol. 2020;34(5):e212–3. DOI: 10.1111/jdv.16387
DOI: https://doi.org/10.1111/jdv.16387
Yan Z, Wei C, Meng X, Yuanjie L, Yang Y, Jing Z, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Chinese J Hematol [Internet]. 2020;41(04):302–7. Available from: DOI: 10.3760/cma.j.issn.0253-2727.2020.008
Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700. DOI: 10.1016/j.jaad.2020.04.018
DOI: https://doi.org/10.1016/j.jaad.2020.04.018
OMS. Síndrome inflamatorio multisistémico en niños y adolescentes con COVID-19. Inf científico. 2020;1–3. WHO reference number: WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1
Organización Panamericana de la Salud / Organización Mundial de la Salud. Alerta Epidemiológica complicaciones y secuelas por. Ops/Oms. 2020; https://www.paho.org/es/documentos/alerta-epidemiologica-complicaciones-secuelas-por-covid-19-12-agosto-2020
Grupo ACIN. Consenso Colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV-2/COVID-19 en establecimientos de atención de la salud. INFECTIO [Internet]. 2020;24(3):14–24. Available from: http://www.iets.org.co/Archivos/853-2765-1-PB.pdf
DOI: https://doi.org/10.22354/in.v24i3.851
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93. doi: 10.2214/AJR.20.23034
DOI: https://doi.org/10.2214/AJR.20.23034
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5
DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Med J Chinese People’s Lib Army. 2020;45(1):1–20. DOI: 10.1186/s40779-020-0233-6
DOI: https://doi.org/10.1186/s40779-020-0233-6
Cheng VC, Edwards KM, Gandhi R, Muller WJ. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. 2020. DOI: 10.1093/cid/ciaa478
DOI: https://doi.org/10.1093/cid/ciaa478
Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–32. DOI: 10.1080/22221751.2020.1746199
DOI: https://doi.org/10.1080/22221751.2020.1746199
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020;1–13. DOI : 10.1056/NEJMoa2031994
Food and drug administration. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 [Internet]. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–31. DOI: 10.1056/NEJMoa2022483
DOI: https://doi.org/10.1056/NEJMoa2022483
Pfizer. PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19 [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world
Pfizer. PFIZER AND BIONTECH ANNOUNCE PUBLICATION OF RESULTS FROM LANDMARK PHASE 3 TRIAL OF BNT162B2 COVID-19 VACCINE CANDIDATE IN THE NEW ENGLAND JOURNAL OF MEDICINE [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark
Randall T, Sam C, Tartar A, Murray P, Cannon C. COVID 19 vaccine tracker global distribution [Internet]. 2021. Available from: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
WHO. Status of COVID-19 Vaccines within WHO EUL / PQ evaluation process. Who. 2021;26(December 2020):2020–2.
(FDA) TU. F and DA. EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19). 2021. p. 1–30. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use
Centros para el Control y la prevención de Enfermedades. Pfizer-BioNTech [Internet]. 2021 [cited 2021 Feb 6]. Available from: https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. DOI: 10.1016/S1473-3099(20)30843-4
DOI: https://doi.org/10.1016/S1473-3099(20)30843-4
Bischler A. Dosing information for AstraZeneca COVID-19 Vaccine [Internet]. 13 January. 2021 [cited 2021 Feb 5]. Available from: https://www.sps.nhs.uk/articles/dosing-information-for-astrazeneca-covid-19-vaccine/
AstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. 3 February. 2021 [cited 2021 Feb 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html
Products M& H, Regulatory Agency. Information for Healthcare Professionals on COVID- 19 Vaccine AstraZeneca. 2021. p. 1–14. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca-regulation-174
Instituto de Efectividad Clínica y Sanitaria (IECS). Vacunas contra COVID-19 2. 2020. p. 1–18. Avaible at: https://docs.bvsalud.org/biblioref/2020/12/1140939/iecs-irr-814-va-1-3.pdf
National Institutes of Health. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released [Internet]. January 29. 2021. Available from: https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released
Levine H. COVID-19 Update: Your Latest Questions About Johnson & Johnson’s Investigational Vaccine Candidate Answered [Internet]. 2021 [cited 2021 Feb 5]. Available from: https://www.jnj.com/innovation/questions-about-johnson-johnson-investigational-covid-19-vaccine
Batres O. Vacuna Covid Janssen: la dosis única genera anticuerpos en el 90% de casos [Internet]. Redacción médica. 2021 [cited 2021 Feb 5]. Available from: https://www.redaccionmedica.com/secciones/sanidad-hoy/vacuna-covid-janssen-dosis-unica-anticuerpos-5331
Branswell H. Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson [Internet]. STAT. 2021 [cited 2021 Feb 5]. Available from: https://www.statnews.com/2021/02/02/comparing-the-covid-19-vaccines-developed-by-pfizer-moderna-and-johnson-johnson/
Microbiology TGNC of E and. Sputnik V, The first registered COVID-19 vaccine proven human adenoviral vector technology [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://sputnikvaccine.com/esp/about-vaccine/
Ministerio de Salud de Argentina. Campaña Nacional de Vacunación contra la COVID-19. 2o informe de vigilancia de seguridad de vacunas. [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://www.fundacionfemeba.org.ar/blog/farmacologia-7/post/efectos-adversos-de-la-vacuna-sputnik-v-48739
Pdf
FLIP
